Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies

Area of Science:

• Hematology
• Immunology
• Clinical Diagnostics

Background:

• Minimal residual disease (MRD) quantification post-therapy shows prognostic value in mature B-cell malignancies.
• Advancements in flow cytometry, including multi-color analysis and standardization, position it as a preferred MRD assessment tool for certain lymphomas.

Purpose of the Study:

• To outline general principles of flow cytometry standardization for MRD detection.
• To illustrate technical standardization strategies using chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) as examples.
• To focus on MRD data acquisition and analysis in MM and CLL based on EuroFlow strategies.

Main Methods:

• Description of general aspects of flow cytometric standardization.
• Application of EuroFlow strategies for technical standardization in MRD detection.
• Detailed explanation of MRD data acquisition and analysis protocols for CLL and MM.

Main Results:

• Standardization of flow cytometry enables reliable MRD quantification.
• EuroFlow strategies provide a framework for consistent MRD assessment.
• Specific protocols for MM and CLL facilitate accurate MRD detection and analysis.

Conclusions:

• Standardized flow cytometry is essential for reliable MRD assessment in B-cell malignancies.
• The described methods and strategies enhance the prognostic significance of MRD detection.
• This approach supports improved patient management and therapeutic strategies in CLL and MM.